Amjad Khan

From AI as a Tool to AI as a Co-Worker: Operationalising Augmented Intelligence and Automation to Optimise mRNA Development & CMC

As mRNA programmes scale in complexity and regulatory scrutiny, teams are under pressure to deliver faster, more robust development without increasing operational burden. While AI and automation are widely discussed, many organisations still struggle to translate these capabilities into practical, connected workflows that materially improve how work gets done across development and CMC.

Led by Pfizer and BioNTech, this workshop will explore how augmented intelligence and automation can be operationalised, enabling more efficient process development, stronger CMC alignment, and improved regulatory readiness. Attendees will gain insight into where AI and automation deliver immediate value, and how digitally enabled workflows can reduce friction while preserving quality and compliance.

• Reframing AI from point solutions to augmented workflows that materially change how mRNA teams operate across development, CMC, and regulatory preparation
• Exploring how low-code platforms, agentic AI, and workflow automation can compress timelines, reduce operational friction, and free scientists to focus on decision-making
• Identifying where AI delivers immediate value outside the lab, including regulatory readiness, documentation, submission quality, and cross-functional coordination